Nasdaq · CIK 0001131343
ATHE ALTERITY THERAPEUTICS LTD
Insider trading from SEC Form 4. Last filing 35 d ago. Close $3.12 on Oct 9, 2026, +7% from the 52-week low and -47% from the high.
In brief
ALTERITY THERAPEUTICS LTD (ATHE) has 4 SEC Form 4 filings on file from 4 insiders, the latest filed on Sep 8, 2026. In the last 90 days insiders made 1 open-market buy worth $24k and 0 open-market sells worth $0, net +$24k.
1 open-market trade has been scored at ATHE. The newest: Peter Ashley Marks (director) bought $24k of stock on Aug 31, 2026, filed Sep 8, 2026, scored 21 (weak).
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ALTERITY THERAPEUTICS LTD, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | Peter Ashley Marks director buy | $24k 47,620 shares | +33% | - |
Transactions
Every row filed, 5 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Peter Ashley Marks director | POpen-market purchase Ordinary sharesindirect: Lampam Pty Ltd | +47,620 | $0.50 | $24k | 191,340 | 35 d ago |
| Aug 31, 2026 | David Allen Stamler Chief Executive Officer | POpen-market purchase Listed option exp 31 Aug 2026derivative | -47,620 | $0.50 | $24k | 0 | 35 d ago |
| Aug 31, 2026 | Peter Ashley Marks director | POpen-market purchase Listed option exp 31 Aug 2026derivativeindirect: Lampam Pty Ltd | -47,620 | $0.50 | $24k | 0 | 35 d ago |
| Jun 15, 2026 | Lawrence Bernard Gozlan director | AGrant or award Listed option exp 15 Jun 2031derivativeindirect: Montoya Pty Ltd <Buttercup A/C> | +1,000,000 | $0.00 | $0 | 1,000,000 | Jun 23, 2026 |
| Jun 15, 2026 | Julian Michael Babarczy director | AGrant or award Unlisted option exp 15 Jun 2031derivativeindirect: Vaucluse Investment Holdings Pty Ltd <Jigsaw Investment A/C> | +2,000,000 | $0.00 | $0 | 2,000,000 | Jun 23, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Julian Michael Babarczydirector
- Lawrence Bernard Gozlandirector
- Peter Ashley Marksdirector
- David Allen StamlerChief Executive Officer
Questions about ATHE
Answered from the filings on this page, as of the latest one.
Are insiders buying ATHE?
As of Sep 8, 2026, SEC Form 4 filings show 1 open-market buy worth $24k by 1 insider and 0 open-market sells worth $0 by 0 insiders at ALTERITY THERAPEUTICS LTD in the last 90 days, net +$24k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade ATHE on the open market?
Peter Ashley Marks (director) bought $24k of ATHE on Aug 31, 2026 and filed the Form 4 on Sep 8, 2026. InsiderTell scored 21 (weak).
How many insiders file Form 4 at ALTERITY THERAPEUTICS LTD?
4 people have filed a Form 4 at ALTERITY THERAPEUTICS LTD, among them Julian Michael Babarczy (director), Lawrence Bernard Gozlan (director), Peter Ashley Marks (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.